EXPRESSION OF METASTASIS ASSOCIATED PROTEIN 1 AS A POSSIBLE PROGNOSTIC INDICATOR IN ORAL SQUAMOUS CELL CARCINOMA | ||||
| Alexandria Dental Journal | ||||
| Article 14, Volume 42, Issue 2, December 2017, Page 210-214 PDF (505.42 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/adjalexu.2017.57929 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Wedad M. Nawar* 1; Taissir A. Omar2; Hamed A. Fouad2; Gamal A. Swaify3 | ||||
| 1Resident in Oral Pathology Department, Faculty of Dentistry, Alexandria University | ||||
| 2- Professor in Oral Pathology Department. | ||||
| 3Professor in Cranio Maxillofacial and Plastic Surgery | ||||
| Abstract | ||||
| INTRODUCTION: Lymph node (LN) metastasis is one of the most important prognostic factors related to survival of oral squamous cell carcinoma (OSCC). Although, metastasis associated protein 1 (MTA1) overexpression is closely correlated with the metastasis of several human cancers, its role in determining lymph node metastases in OSCC patients remains undefined. Proliferating Cell Nuclear Antigen (PCNA) is the most representative proliferating marker; yet there is a controversy as to whether it can be used as a prognostic marker in OSCC. OBJECTIVES: To evaluate the immunoexpression of MTA1 and PCNA in metastatic versus non-metastatic OSCC; and correlate it with LN metastasis. MATERIALS AND METHODS: MTA1 and PCNA immunoexpression was detected immunohistochemically in 20 OSCC specimens; 10 of which had metastatic LNs and 10 with non-metastatic LNs (used as a control group). Their correlation with LN metastasis was evaluated. RESULTS: MTA1 immunoexpression showed significant correlation with LN metastasis but not with the histologic grade of the tumor. Whereas, PCNA immunoexpression revealed a significant correlation with the histologic grade of the tumor, but not with nodal metastasis. CONCLUSIONS: The present study suggests that MTA1 protein may have a clinical potential to be used as a prognostic factor to identify pathologically node-negative OSCC patients who may be at high risk to develop regional metastasis. On the other hand, PCNA is unlikely to play an important role in predicting LN metastasis in OSCC patients. | ||||
| Keywords | ||||
| OSCC; MTA1; PCNA; LN metastasis | ||||
| References | ||||
|
1. Yang YH, Sue RL, Warnakulasuriya S, Dasanayake AP. Promoting better oral health practices among aboriginal Taiwanese adolescents: a school based oral health education intervention program. J Health Care Poor Underserved. 2009; 20:41-50.
2. Shah JP, Candela FC, Poddar AK. The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. Cancer. 1990; 66:109-13.
3. Beenken SW, Urist MM. Head and neck tumors. In: Way LW, Doherty GM, editors. Current surgical diagnosis and treatment. 11th ed. New York: Lange Medical Books/McGraw-Hill; 2003: 282-97.
4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer Incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136: E359-86.
5. World Health Organization. The World Oral Health Report 2003. Geneva: WHO; 2003.
6. U.S. Department of Health and Human Services. Oral health in America: a report of the Surgeon General— executive summary. Rockville (MD): US Department of Health and Human Services, National Institute of Dental and Craniofacial Research, National Institutes of Health; 2000. 1-13.
7. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011; 11:9-22.
8. Kumar R, Wang RA, Bagheri-Yarmand R. Emerging roles of MTA family members in human cancers. Semin Oncol. 2003; 30:30–7.
9. Li SH, Tian H, Yue WM, Li L, Gao C, Li WJ, et al. Metastasis-associated protein 1 nuclear expression is closely associated with tumor progression and angiogenesis in patients with esophageal squamous cell cancer. World J Surg. 2012; 36:623–31.
10. Lee SH, Chung YH, Kim JA, Lee D, Yin YJ, Shim JH, et al. Single nucleotide polymorphisms associated with metastatic tumour antigen 1 overexpression in patients with hepatocellular carcinoma. Liver Int. 2012; 32:457–66.
11. Dias SJ, Zhou X, Ivanovic M, Gailey MP, Dhar S, Zhang L, et al. Nuclear MTA1 overexpression is associated with aggressive prostate cancer, recurrence and metastasis in African Americans. Sci Rep. 2013; 3:2331.
12.Roepman P, de Jager A, Groot Koerkamp MJ, Kummer JA, Slootweg PJ, Holstege FC. Maintenance of head and neck tumor gene expression profiles upon lymph node metastasis. Cancer Res. 2006; 66:11110–14.
13. Kawasaki G, Yanamoto S, Yoshitomi I, Yamada S, Mizuno A. Overexpression of metastasis-associated MTA1 in oral squamous cell carcinomas: correlation with metastasis and invasion. Int J Oral Maxillofac Surg. 2008; 37:1039–46.
14. Kato K, Kawashiri S, Yoshizawa K, Kitahara H, Okamune A, Sugiura S, et al. Expression form of p53 and PCNA at the invasive front in oral squamous cell carcinoma: correlation with clinicopathological features and prognosis. J Oral Pathol Med. 2011; 40:693-8.
15. Diamandis EP, Christopoulos TK. The Biotin-(Strept) Avidin System: Principles and Applications in Biotechnology Clin Chem. 1991; 37:625-36.
16. Yin S, Li Z, Huang J, Zhang J, Lu C, Xu H, et al. Prognostic value and clinicopathological significance of proliferating cell nuclear antigen expression in gastric cancer: a systemic review and meta-analysis. Onco Targets Ther. 2017; 10:319-27.
17. Abdulkadir S, Ali NR, Alchalabi NJ. Pathological study of oral squamous cell carcinoma by application of p53 and PCNA (immunohistochemical approach). Int J Curr Microbiol App Sci. 2016; 5:91-100.
18. Myoung H, Jim MJ, Lee JH, Ok YJ, Paeng JY, Yun PY. Correlation of proliferative markers (ki-67 and PCNA) with survival and lymph node metastasis in oral squamous cell carcinoma: a clinical and histopathological analysis of 113 patients. Int J Oral Maxillofacial Surg. 2006; 35:1005-10.
19. Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, et al. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res. 2004; 64:825-9.
20. Martin MD, Hilsenbeck SG, Mohsin SK, Hopp TA, Clark GM, Osborne CK, et al. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat. 2006; 95:7–12.
21. Deng X, Du L, Wang C, Yang Y, Li J, Liu H, et al. Close association of metastasis-associated protein 1 overexpression with increased angiogenesis and poor survival in patients with histologically node-negative gastric cancer. World J Surg. 2013; 37:792-8.
22. Kaur E, Gupta S, Dutt S. Clinical Implications of MTA proteins in human cancer. Cancer Met Rev. 2014; 33:1017- 24.
23. Hofer MD, Tapia C, Browne TJ, Mirlacher M, Sauter G, Rubin MA. Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue. Arch Pathol Lab Med. 2006; 130:989–96.
24. Balasenthil S, Broaddus RR, Kumar R. Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Human Pathol. 2006; 37:656–61.
25. Moon WS, Chang K, Tarnawski AS. Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: relationship to vascular invasion and estrogen receptoralpha. Hum Pathol. 2004; 35:424-9.
26. Liu J, Xu D, WangH, Zhang Y, Chang Y, Zhang J, et al. The subcellular distribution and function of MTA1 in cancer differentiation. Oncotarget. 2014; 5:5153-64.
27. Aramaki Y, Ogawa K, Toh Y, Ito T, Akimitsu N, Hamamoto H, et al. Direct interaction between metastasisassociated protein 1 and endophillin 3. FEBS Letter, 2005;579:3731-6.
28. Luo H, Li H, Yao N, Hu L, He T. Metastasis-associated protein 1 as a new prognostic marker for solid tumors: a metanalysis of cohort studies. Tumour Biol. 2014; 35:5823- 32.
29. Liu T, Yang M, Yang S, Ge T, Gu L, Lou G. Metastasisassociated protein 1 is a novel marker predicting survival and lymph nodes metastasis in cervical cancer. Hum Pathol. 2013; 44:2275-81.
30. Ahmed M. Expression profile of apoptotic mediators and proliferative markers in oral squamous cell carcinoma. J Egypt Natl Canc Inst. 2009; 21:85-92.
31. Fan J, Zhou X, Huang J, Wang X, Che G. Prognostic roles of PCNA expression in non-small cell lung cancer: a metaanalysis. Int J Clin Exp Med. 2016; 9:5655-65.
32. Pena L, Nieto A, Perez-Alenza D, Cuesta P, Castano M. Immunohistochemical detection of ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables. J Vet Diagn Invest. 1998; 10:237-46.
33. Al Azzawi LM. Immunohistochemical analysis of PCNA and p53 proteins in oral lichen planus, oral dysplasia and normal oral mucosa. DJM. 2014; 6:41-7.
34. Tanai, M, Tomimatsu M, Okuda H, Saito A, Obata H. Immunohistochemical detection of proliferating cell nuclear antigen in hepatocellular carcinoma: relationship to histological grade. J Gastroenterol Hepatol. 1998; 8:420-5.
35. Adachi E, Hashimoto H, Tsuneyoshi M. Proliferating Cell Nuclear Antigen in Hepatocellular Carcinoma and small cell liver dysplasia. Cancer. 1993; 72:2902-9.
36. Kitamoto M, Nakanishi T, Kira S, Kawaguchi M, Nakashio R, Suemori S, et al. The assessment of proliferating cell nuclear antigen immunohistochemical staining in small hepatocellular carcinoma and its relationship to histologic characteristics and prognosis. Cancer. 1993; 72:1859-65.
37. Micozkadioglu D, Unal M, Pata YS, Basturk M, Cinel L. Prognostic value of expression of p53, proliferating cell nuclear antigen and c-erb02 in laryngeal carcinoma. Med Sci Monit. 2008;14:CR299-304.
38. Madan M, Chandra S, Raj V, Madan R. Evaluation of cell proliferation in malignant and potentially malignant oral lesions. J Oral Maxillofac Pathol. 2015; 19:297-305.
39. Staibano S, Mignogna MD, Muzio LL, Alberti L, Natale E, Lucariello A, et al. Overexpression of cyclin-D1, bcl-2 and bax proteins, proliferationg cell nuclear antigen (PCNA), and DNA-ploidy in squamous cell carcinoma of the oral cavity. Hum Pathol. 1998; 29:1189-94.
| ||||
|
Statistics Article View: 93 PDF Download: 289 |
||||
